


Precision oncology demands precision.


The most accurate and comprehensive workflow on the market for oncology NGS¹, brought to you by Illumina informatics.



Powered by DRAGEN™ secondary analysis, winner of the PrecisionFDA Truth Challenge, and Illumina Connected Insights variant interpretation and reporting.

Laboratory		TruSight™ Oncology 500 Report	
Case ID: DEMO_G01_OVARIAN		Reported: 2025-07-23 12:18 (PT)	Disease: Malignant tumor of ovary
Sex: Female		Sample type: RNA & DNA	Sample Name(s): -
Interpretation Summary			
Testing revealed a BRCA1 mutation with possible hereditary risk implications. Tumor is HRD-positive as indicated by the BRCA1 variant and high GIS score (56). TP53 mutation was also identified.			
Findings			
Tier 1A			
BRCA1 p.(Trp1815Ter) (WFS15*) Tumor VAF 83.44%	Likely Oncogenic Hereditary Risk	Therapeutic	→ Responsive: Bevacizumab + Olaparib, Niraparib, Olaparib, Rucaparib
GIS 56	GIS-High HRD Positive	Therapeutic	→ Responsive: Bevacizumab + Olaparib
TMB 11.8 mut/MB	TMB-High	Therapeutic	→ Responsive: Pembrolizumab
Tier 1B			
TP53 p.(Tyr183Cys) (T183C3) Tumor VAF 12.13%	Likely Oncogenic	Therapeutic	→ Responsive: Adavosertib + Carboplatin, Adavosertib + Carboplatin + Paclitaxel
Tier 2C			
ATR c.2078_2078+1Tdel Tumor VAF 5.43%	Likely Oncogenic	Therapeutic	→ Responsive: Enzalutamide + Talazoparib (Prostate Cancer)
dgap19(c24.2) NVC Gain Copy number: 9 Fold change: 1.527	Oncogenic	AR Clinical trials	→ Available: See clinical trials section
ESR1-CCDC170 Translocation Tumor VAF 8.50%	Oncogenic	Therapeutic	→ Responsive: Elexstrant (Her2-receptor negative breast cancer)
Genomic biomarkers reported: <ul style="list-style-type: none">Tumor Mutational Burden (TMB) 11.8 mut/MB (TMB-High)Microsatellite Instability (MSI) 0% unstable sites (MSI-Stable)Genomic Instability Score (GIS) 56 (GIS-High)			
Patient negatives reported: <ul style="list-style-type: none">ATM, BRCA2, BRIP1, FDXL2, MLH1, MSH2, MSH6, NBN, NTRK1, NTRK2, NTRK3, PALB2, PMS2, RADS1C, RADS1D, STK11			
Report signed off on 2025-07-23 12:18 (PT)		Page 1 of 2	

Unlock meaning for a wide range of clinical research applications all within a single interface




Solid tumor




Liquid biopsy



Heme



Methylation



Expression



MRD and monitoring

Targeted Panels

CGP

WTS

WES

WGS

User friendly

- Easy-to-use, turnkey oncology workflows
- Automated from sample to report
- Self-serve customizations in a single intuitive interface

Operational efficiency

- One provider for any application or volume
- Short turnaround times powered by world record speeds of DRAGEN²⁻³
- Seamless compatibility with Illumina assays and instruments

Powered for growth

- Award-winning variant calling accuracy with DRAGEN⁴⁻⁵
- Broad coverage of oncology variant classes, gene signatures
- Respected knowledge sources (CKB and OncoKB)

One workflow. One trusted provider.

Go from sample to draft report faster.



“ We load the sequencer and the data shows up. It’s automated, it’s fast, and we don’t have to perform any manual interventions—we’re not waiting 12 hours for somebody to wake up and kick off the pipeline.”

Melissa Kelly, PhD
Clinical Laboratory Director
JAX Advanced Precision Medicine Laboratory



Want to learn more about Illumina informatics?

Visit ilmn.ly/oncology-informatics

1. DRAGEN secondary analysis when compared against leading secondary analysis players who have submitted to [PrecisionFDA v2 Truth Challenge Benchmark Data](#). Illumina internal data on file, 2023.
2. When compared against leading secondary analysis players who have submitted to [PrecisionFDA v2 Truth Challenge Benchmark Data](#)
3. Illumina Internal Data on File, 2023
4. Reported by Illumina FastTrack Lab and Illumina data on file (2023)
5. Illumina Internal Data on File 2023, PrecisionFDA Truth Challenge V2: Calling Variants from Short and Long Reads in Difficult-to-Map Regions. precision.fda.gov/challenges/10.